Clinical Trials
982 trials[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
Aalborg University Hospital
Nano-X
University of Sydney
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines Inc.
Augmented Whole-body Scanning Via Magnifying PET/CT (AWSM-PET/CT) Techniques Abilities to Improve Upon the Diagnostic Accuracy of the Standard-of-care (SOC) PET/CT for Malignant Lesion Detection
Washington University School of Medicine
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
A Phase 1 Study of NM6603 in Advanced Solid Tumors
NucMito Pharmaceuticals Co. Ltd.
Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients
National Institutes of Health Clinical Center (CC)
UPSIT
Ohio State University
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer
The First Affiliated Hospital of Xiamen University
Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy
Kaiser Permanente
Maladaptive Adipose Tissue Activity in Cancer
Virginia Commonwealth University
CLEAR
Harbinger Health
eGAP
University of Rochester
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
LAUREL
Inmune Bio, Inc.
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
Vividion Therapeutics, Inc.
ARFIM
Institut Bergonié
Study of Combined Decompressive Spine Radiosurgery and Pembrolizumab
Wake Forest University Health Sciences
NBI-CAB
Centre Oscar Lambret
MorphinOgel
University Hospital, Strasbourg, France
MESO-PATCH
Centre Oscar Lambret
ANOXICOL
Centre Oscar Lambret
NeuroPrevPTSD
Centre Oscar Lambret
SUPR-3D: Simple Unplanned Palliative Radiotherapy Versus 3D Conformal Radiotherapy for Patients With Bone Metastases
British Columbia Cancer Agency
NEPENTHE
Children's Hospital of Philadelphia
AcceleRET-Lung
Hoffmann-La Roche
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
PORTICO
Luzerner Kantonsspital
PERLE
Assistance Publique - Hôpitaux de Paris
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
A Study of PHN-010 in Patients With Advanced Solid Tumors
Pheon Therapeutics
TRIPLEX
Norwegian University of Science and Technology
Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)
GlaxoSmithKline
EC-PC
University of Washington
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
Sanofi
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Bristol-Myers Squibb
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors
National Institutes of Health Clinical Center (CC)
TOPOLOGY
Institut Curie
Discovering Cancer Risks From Environmental Contaminants and Maternal/Child Health
University of California, San Francisco
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
CytomX Therapeutics
HAMMER
Synthorx, Inc, a Sanofi company
IPOD-3
Société des Produits Nestlé (SPN)
Screening of Cancer Patients to Assess Impact of COVID-19
University Health Network, Toronto
PRESAGE
Assistance Publique - Hôpitaux de Paris
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Elevation Oncology